Patients
Tumors, infection, adenosquamous cell carcinoma, autoimmune or inflammatory disorders
PRIMARY IMMUNODEFICIENCY, TUMORS, INFECTION, ADENOSQUAMOUS CELL CARCINOMA, ONCOLOGY
Patients who were eligible for the ESCC cohort included adults aged ≥18 years with histologically or cytologically documented locally advanced unresectable or metastatic ESCC who were candidates for first‐line therapy. Patients with adenosquamous cell carcinoma were eligible for enrollment if squamous cell was the predominant type. Patients who had received neoadjuvant, adjuvant, or definitive chemotherapy or radiotherapy were eligible if the last dose was administered ≥6 months prior to enrollment. Eligible patients had no prior exposure to immune‐mediated therapy, including anti‐PD‐1, anti‐PD‐L1, anti‐PD‐L2, or anti‐CTLA‐4 antibodies, and therapeutic anticancer vaccines. Patients must have had at least one lesion ≥10 mm in diameter with computed tomography or magnetic resonance imaging scans suitable for repeated measurements, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guidelines, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and a life expectancy ≥12 weeks. Patients were not eligible if they had active or prior documented autoimmune or inflammatory disorders, history of active primary immunodeficiency, or active infection.